Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01HQU
|
|||
| Drug Name |
AK107
|
|||
| Synonyms |
2,5-Bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]-1,3-oxazole; AK.107; AC1LARBL; CTK5J5532; 2,5-bis[4-(1H-imidazol-2-yl)phenyl]oxazole; 2,5-Bis(4-imidazol-2-ylphenyl)-1,3-oxazole
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Akeso Biopharma Guangdong, China Merck Kenilworth, NJ
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H15N5O
|
|||
| Canonical SMILES |
C1=CC(=CC=C1C2=CN=C(O2)C3=CC=C(C=C3)C4=NC=CN4)C5=NC=CN5
|
|||
| InChI |
1S/C21H15N5O/c1-3-15(19-22-9-10-23-19)4-2-14(1)18-13-26-21(27-18)17-7-5-16(6-8-17)20-24-11-12-25-20/h1-13H,(H,22,23)(H,24,25)
|
|||
| InChIKey |
POIOBVFAFSUWGR-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immune checkpoint (ICH) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.